January 21, 2021
Business News

DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

LOS ANGELES–()–The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioMarin Pharmaceutical Inc. (“BioMarin” or “the Company”) (NASDAQ: BMRN) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. BioMarin’s Phase 3 trial of valoctocogene roxaparvovec differed from its Phase 1/2 trial, which lowered the reliability of the earlier study’s data on durability of effect. This put the Company at risk of the FDA not approving the BLA for valoctocogene roxaparvovec without the submission of…

Click here to view the original article.

Related Posts

You might also like ...

Sapreme Appoints Henrik Luessen as Chief Business Officer
Servier and MiNA Therapeutics Enter Collaboration in Neurological Diseases
smartTrade Reports Successful 2020, Looks Forward to Strong Growth In 2021